CTI Anticipates Preliminary Data From Pivotal Pixantrone Trial In Mid-2008
Firm is forging ahead with non-Hodgkin’s lymphoma program following positive special protocol assessment from FDA.
Firm is forging ahead with non-Hodgkin’s lymphoma program following positive special protocol assessment from FDA.